These recommendations advocated for utilizing multifaceted cardiac surveillance tests, such as echocardiogram and B-type natriuretic peptide (BNP), for early detection of cardiac dysfunction among breast cancer patients who received anthracycline therapy [27–30]. Here, NPPB is linked to breast cancer.